These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A long‑term complete response to namodenoson in liver cancer with Child‑Pugh B cirrhosis: A case report. Ciurescu IA; Lencioni R; Stemmer SM; Farbstein M; Harpaz Z; Bareket-Samish A; Silverman MH; Fishman P Exp Ther Med; 2024 Jun; 27(6):263. PubMed ID: 38756903 [TBL] [Abstract][Full Text] [Related]
4. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Safadi R; Braun M; Francis A; Milgrom Y; Massarwa M; Hakimian D; Hazou W; Issachar A; Harpaz Z; Farbstein M; Itzhak I; Lev-Cohain N; Bareket-Samish A; Silverman MH; Fishman P Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1405-1415. PubMed ID: 34671996 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child-Pugh B liver function at study week 8: a retrospective analysis of the CELESTIAL randomised controlled trial. El-Khoueiry AB; Meyer T; Cheng AL; Rimassa L; Sen S; Milwee S; Kelley RK; Abou-Alfa GK BMC Cancer; 2022 Apr; 22(1):377. PubMed ID: 35397508 [TBL] [Abstract][Full Text] [Related]
6. Hepatocellular Carcinoma: A Phase II Randomized Controlled Double-Blind Trial of Transarterial Chemoembolization in Combination with Biweekly Intravenous Administration of Bevacizumab or a Placebo. Pinter M; Ulbrich G; Sieghart W; Kölblinger C; Reiberger T; Li S; Ferlitsch A; Müller C; Lammer J; Peck-Radosavljevic M Radiology; 2015 Dec; 277(3):903-12. PubMed ID: 26131911 [TBL] [Abstract][Full Text] [Related]
7. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Kang YK; Yau T; Park JW; Lim HY; Lee TY; Obi S; Chan SL; Qin S; Kim RD; Casey M; Chen C; Bhattacharyya H; Williams JA; Valota O; Chakrabarti D; Kudo M Ann Oncol; 2015 Dec; 26(12):2457-63. PubMed ID: 26386123 [TBL] [Abstract][Full Text] [Related]
8. Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma. Etzion O; Bareket-Samish A; Yardeni D; Fishman P Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672201 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma. Ryoo BY; Palmer DH; Park SR; Rimassa L; Debashis Sarker ; Daniele B; Steinberg J; López B; Lim HY Clin Drug Investig; 2021 Sep; 41(9):795-808. PubMed ID: 34351608 [TBL] [Abstract][Full Text] [Related]
10. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study. Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879 [TBL] [Abstract][Full Text] [Related]
11. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M; Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869 [TBL] [Abstract][Full Text] [Related]
12. Atezolizumab plus bevacizumab in patients with child-Pugh B advanced hepatocellular carcinoma. Cheon J; Kim H; Kim HS; Kim CG; Kim I; Kang B; Kim C; Jung S; Ha Y; Chon HJ Ther Adv Med Oncol; 2023; 15():17588359221148541. PubMed ID: 37705533 [TBL] [Abstract][Full Text] [Related]
13. Nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis: Safety and clinical outcomes in a retrospective case series. Thiruvengadam S; Bauer KE; Bracci PM; Keenan BP; Behr SC; Gordan JD; Kelley RK Cancer; 2019 Sep; 125(18):3234-3241. PubMed ID: 31154669 [TBL] [Abstract][Full Text] [Related]
14. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma as first-line therapy. Oh MJ; Lee HJ; Lee SH Clin Mol Hepatol; 2013 Sep; 19(3):288-99. PubMed ID: 24133667 [TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase II Open-Label Multi-Institution Study of the Combination of Bevacizumab and Erlotinib Compared to Sorafenib in the First-Line Treatment of Patients with Advanced Hepatocellular Carcinoma. Thomas MB; Garrett-Mayer E; Anis M; Anderton K; Bentz T; Edwards A; Brisendine A; Weiss G; Siegel AB; Bendell J; Baron A; Duddalwar V; El-Khoueiry A Oncology; 2018; 94(6):329-339. PubMed ID: 29719302 [TBL] [Abstract][Full Text] [Related]